FAKTOR OPTIONSSCHEIN - NOVO-NORDISK B | Delayed Deutsche Boerse AG 15:21:02 21/05/2024 BST | ||
| 196.3 EUR | +4.87% |
|
| 1 month | +5.90% | ||
| 3 months | +10.71% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 21/05/24 | 196.3 | +4.87% |
| 17/05/24 | 187.2 | -2.34% |
| 16/05/24 | 191.6 | -0.92% |
| 15/05/24 | 193.4 | +1.76% |
| 14/05/24 | 190.1 | +0.39% |
Delayed Quote Deutsche Boerse AG
Last update May 21, 2024 at 03:21 pm
More quotesStatic data
| Product type | Exotische Produkte |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| WKN | PX2N0V |
| ISIN | DE000PX2N0V3 |
| Date issued | 11/03/2019 |
| Strike | 903.3 kr |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 10.05 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 200 € |
|---|---|
| Lowest since issue | 9.08 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
903.3
DKK
Average target price
909.2
DKK
Spread / Average Target
+0.66%
- Stock Market
- Certificates
- Certificat
